C1QC and congenital rubella syndrome: Moreover, the targets of cetuximab (viz., epidermal growth factor receptor, complement C1q A chain (C1QA), C1QB, C1QC, Fc gamma receptor (FCGR) 1A, FCGR2A, FCGR3A, and FCGR2B) and atezolizumab (viz., CD274) were also highly expressed in the high-CRS subgroup, suggesting that patients in this subgroup were more responsive to these chemotherapeutic and targeted drugs (Figure 7(b)).